KYN-5356is an innovative, first-in-class small molecule that targets KAT-II, a key enzyme in the kynurenine pathway Topline results are expected in the second half of 2024 ‍Naarden, The Netherlands – January 4, 2024 – Kynexis, a biotechnology company focused on precision therapeutics by leveraging biomarkers and human genetics for brain diseases, announced today that the first … Continue reading Kynexis Announces Initiation of First-in-Human Phase 1 Study of KYN-5356, a Potential Treatment for Cognitive Impairment Associated with Schizophrenia